LETERMOVIR (Prevymis®)

Clinical Indication

Prevention of cytomegalovirus disease after a stem cell transplant


In line with NICE TA591

Implementation date 31st October 2019

Date of classification

October 2019

Review date

October 2019


Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).